Patents by Inventor Vincenzo Summa

Vincenzo Summa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20230151027
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 18, 2023
    Applicants: Ospedale San Raffaele S.r.l., Istituto Nazionale Genetica Molecolare - INGM
    Inventors: Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Adolfo PRANDI, Marilenia DE MATTEO, Pietro RANDAZZO
  • INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20230076319
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: October 4, 2022
    Publication date: March 9, 2023
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Davide GORNATI, Alessandro GRILLO, Luca FERRANTE, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Marco FERRARA
  • Tricyclic inhibitors of Hepatitis B virus
    Patent number: 11504382
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 22, 2022
    Assignee: Antios Therapeutics, Inc.
    Inventors: Raffaele De Francesco, Lorena Donnici, Luca Guidotti, Matteo Iannacone, Romano Di Fabio, Vincenzo Summa, Adolfo Prandi, Pietro Randazzo, Davide Gornati, Alessandro Grillo, Luca Ferrante, Leda Ivanova Bencheva, Marilenia De Matteo, Marco Ferrara
  • OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20220241241
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: May 25, 2020
    Publication date: August 4, 2022
    Applicants: ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM, OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A.
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Leda IVANOVA BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE, Davide GORNATI, Alessandro GRILLO
  • TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20220110943
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: August 9, 2019
    Publication date: April 14, 2022
    Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Davide GORNATI, Alessandro GRILLO, Luca FERRANTE, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Marco FERRARA
  • INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20210276967
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: July 19, 2019
    Publication date: September 9, 2021
    Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM
    Inventors: Raffaele DE FRANCESCO, Adolfo PRANDI, Pietro RANDAZZO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE
  • Compounds for use in the treatment of kinetoplastid infection
    Patent number: 10815222
    Abstract: The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions containing the compounds and their use in the treatment of kinetoplastid infections.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 27, 2020
    Assignee: C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Ilaria Biancofiore, Alina Ciammaichella, Federica Ferrigno, Steven Harper, Savina Malancona, Jesus Maria Ontoria Ontoria, Giacomo Paonessa, Simona Ponzi, Vincenzo Summa
  • COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION
    Publication number: 20200095232
    Abstract: The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions containing the compounds and their use in the treatment of kinetoplastid infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: March 26, 2020
    Applicant: C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Ilaria BIANCOFIORE, Alina CIAMMAICHELLA, Federica FERRIGNO, Steven HARPER, Savina MALANCONA, Jesus Maria ONTORIA ONTORIA, Giacomo PAONESSA, Simona PONZI, Vincenzo SUMMA
  • HCV NS3 protease inhibitors
    Patent number: 9738661
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 22, 2017
    Assignees: MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Steven Harper, John A. McCauley, Joseph J. Romano, Michael T. Rudd
  • Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC
    Patent number: 9371295
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 21, 2016
    Assignees: IRBM-SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Compounds for use in the treatment of parasitic diseases
    Patent number: 9365541
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 14, 2016
    Assignee: IRBM—SCIENCE PARK S.P.A.
    Inventors: Sergio Altamura, Ilaria Biancofiore, Alberto Bresciani, Federica Ferrigno, Steven Harper, Ralph Laufer, Jesus Maria Ontoria Ontoria, Savina Malancona, Edith Monteagudo, Emanuela Nizi, Maria Vittoria Orsale, Simona Ponzi, Giacomo Paonessa, Vincenzo Summa, Maria Veneziano
  • HCV NS3 protease inhibitors
    Patent number: 9328138
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 3, 2016
    Assignees: MSD Italia S.R.L., Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20150299163
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 22, 2015
    Applicants: IRBM - SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio ALTAMURA, Ilaria BIANCOFIORE, Alberto BRESCIANI, Federica FERRIGNO, Steven HARPER, Ralph LAUFER, Jesus Maria ONTORIA ONTORIA, Savina MALANCONA, Edith MONTEAGUDO, Emanuela NIZI, Maria Vittoria ORSALE, Simona PONZI, Giacomo PAONESSA, Vincenzo SUMMA, Maria VENEZIANO
  • HCV NS3 Protease Inhibitors
    Publication number: 20150266897
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: April 3, 2015
    Publication date: September 24, 2015
    Applicants: MSD ITALIA S.R.L., MERCK SHARP & DOHME CORP.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Maria Emilia Di Francesco, Marco Ferrara, Kevin F. Gilbert, Steven Harper, John A. McCauley, Charles J. McIntyre, Alessia Petrocchi, Marco Pompei, Joseph J. Romano, Michael T. Rudd, John W. Butcher, M. Katharine Holloway
  • COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC
    Publication number: 20150218112
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Application
    Filed: August 7, 2013
    Publication date: August 6, 2015
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Macrocyclic compounds as antiviral agents
    Patent number: 8927569
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: January 6, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley, John W. Butcher, Marcello Di Filippo, Maria Emilia Di Francesco, Marco Ferrara, Joseph J. Romano, Michael T. Rudd
  • COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20140328799
    Abstract: The present invention is directed to compositions comprising inhibitors of hepatitis C virus (HCV) protease and one or more additional therapeutically effective agents. Uses of such compositions as HCV inhibitors and methods of treating infection by HCV by administration of such compositions are also disclosed.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 6, 2014
    Inventors: Steven S. Carroll, John A. McCauley, David B. Olsen, Vincenzo Summa, Michael Rowley, Mark W. Stahlhut, Daria Hazuda
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20140296136
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 2, 2014
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20130178413
    Abstract: The present invention relates to macrocyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: September 16, 2011
    Publication date: July 11, 2013
    Inventors: John A. McCauley, Nigel J. Liverton, Michael T. Rudd, Kevin F. Gilbert, Marco Ferrara, Vincenzo Summa, Benedetta Crescenzi
  • HCV NS3 protease inhibitors
    Patent number: 8377873
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: February 19, 2013
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei